Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2009 Jul;24(7):822-8.
doi: 10.1007/s11606-009-1009-6. Epub 2009 May 20.

Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization

Douglas E Levy  1 , Judy E Garber, Alexandra E Shields
Affiliations
Practice Guideline

Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization

Douglas E Levy et al. J Gen Intern Med. 2009 Jul.

Abstract

Background: BRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing.

Objective: To identify women at high risk of hereditary breast and ovarian cancer and estimate their awareness of and experience with genetic testing for cancer risk.

Design: Analyses of the 2000 and 2005 National Health Interview Surveys.

Participants: Women with no personal history of breast or ovarian cancer (n = 35,116).

Measurements: Risk of hereditary breast or ovarian cancer based on self-reported family history of cancer and national guidelines; self-reported awareness of genetic testing for cancer risk; discussion of genetic testing for cancer risk with a health professional; having undergone genetic testing for breast/ovarian cancer risk.

Results: Using guideline criteria, 0.96% of women were identified as being at high risk of hereditary breast and ovarian cancer. Among high-risk women, 54.04% were aware of genetic testing for cancer risk, 10.39% had discussed genetic testing with a health professional, and 1.41% had undergone testing for breast/ovarian cancer risk. Adjusting for survey year, high-risk women were more likely than average-risk women to have heard of genetic testing for cancer risk (RR, 1.3, 95% CI 1.2-1.4), to have discussed genetic testing with a health professional (RR 5.2, 95% CI 3.6-7.4), and to have undergone genetic testing for breast/ovarian cancer risk (RR 6.8, 95% CI 2.6-18.0).

Conclusions: We find low provision of guideline-recommended advice to women for whom testing may be appropriate and of significant clinical benefit.

PubMed Disclaimer

References

    1. American Society of Clinical Oncology American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397–406. doi: 10.1200/JCO.2003.03.189. - DOI - PubMed
    1. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian V.1.2007. Fort Washington, PA; 2007.
    1. US Preventive Services Taskforce Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143(5):355–61. - PubMed
    1. Myriad Genetics. Myriad Genetics Awarded Three US Patents And Eight International Patents. Salt Lake City, UT; 2001:News release.
    1. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23(2):276–92. doi: 10.1200/JCO.2005.10.042. - DOI - PubMed

Publication types

MeSH terms